Selumetinib, 100mg + Selumetinib, 125mg + Selumetinib, 150mg + Selumetinib, 175mg + Selumetinib, 200mg + Selumetinib, 225mg
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma
Trial Timeline
Feb 28, 2017 → Sep 18, 2020
NCT ID
NCT02768766About Selumetinib, 100mg + Selumetinib, 125mg + Selumetinib, 150mg + Selumetinib, 175mg + Selumetinib, 200mg + Selumetinib, 225mg
Selumetinib, 100mg + Selumetinib, 125mg + Selumetinib, 150mg + Selumetinib, 175mg + Selumetinib, 200mg + Selumetinib, 225mg is a phase 1 stage product being developed by AstraZeneca for Uveal Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02768766. Target conditions include Uveal Melanoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02768766 | Phase 1 | Completed |
Competing Products
20 competing products in Uveal Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 52 |
| Pembrolizumab + Entinostat | Merck | Phase 2 | 52 |
| Pembrolizumab + Olaparib | Merck | Phase 2 | 52 |
| Pembrolizumab 25 MG/1 ML Intravenous Solution | Merck | Phase 2 | 52 |
| AEB071 | Novartis | Phase 1 | 33 |
| LXS196 + LXS196 and HDM201 | Novartis | Phase 1 | 33 |
| DYP688 | Novartis | Phase 1/2 | 41 |
| RAD001 (Everolimus) and Pasireotide (SOM230) LAR | Novartis | Phase 2 | 52 |
| ranibizumab + triamcinolone acetonide | Novartis | Phase 2/3 | 65 |
| Crizotinib | Pfizer | Phase 2 | 51 |
| Dacarbazine + Sunitinib | Pfizer | Phase 2 | 51 |
| AEB071 + MEK162 | Pfizer | Phase 1/2 | 40 |
| Binimetinib + Belinostat | Pfizer | Phase 2 | 51 |
| Ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 1 | 32 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |
| ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| ZIV-Aflibercept + Cemiplimab | Sanofi | Phase 2 | 51 |
| Ziv-Aflibercept | Regeneron Pharmaceuticals | Phase 2 | 51 |
| XmAb®23104 + Yervoy® (ipilimumab) | ICON plc. | Phase 1 | 30 |
| IDE196 + Binimetinib + Crizotinib | IDEAYA Biosciences | Phase 1/2 | 36 |